



B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/435, 14/315, 16/46, G01N 33/563	A2	(11) International Publication Number: WO 00/34317 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/GB99/04119		(74) Agents: SHEARD, Andrew, Gregory et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).
(22) International Filing Date: 8 December 1999 (08.12.99)		
(30) Priority Data: 9826925.1 8 December 1998 (08.12.98) GB 9902139.6 2 February 1999 (02.02.99) GB		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (<i>for all designated States except US</i>): BIOVATION LIMITED [GB/GB]; Investment House, 6 Union Row, Aberdeen AB10 1DQ (GB).		
(72) Inventors; and		
(75) Inventors/Applicants (<i>for US only</i>): CARR, Francis, Joseph [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). ADAIR, Fiona, Suzanne [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). HAMILTON, Anita, Anne [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). CARTER, Graham [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB).		

(54) Title: MODIFYING PROTEIN IMMUNOGENICITY

(57) Abstract

It is known that proteins, or parts of them, may be rendered non- or less immunogenic to humans or other species by identifying one or more potential T cell epitopes and eliminating them by amino acid modification. Conventionally, certain epitopes may be retained in a protein sequence if the peptides constituting such epitopes are present in endogenous human protein, since they would be recognised as "self". However, it has now been found that even self epitopes may give rise to immune reactions. The invention provides for their elimination, for example by recombinant DNA technology, to render them more useful for administration to humans, for example for therapeutic or diagnostic purposes.

Published

Without international search report and to be republished upon receipt of that report.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MODIFYING PROTEIN IMMUNOGENICITY

THE PRESENT INVENTION relates to proteins to be administered especially to humans particularly for therapeutic use but also for use in diagnostic tests. The invention particularly provides for proteins which are modified to be less immunogenic than the unmodified counterpart when used *in vivo*.

The invention particularly addresses the clinical need for a process by which the natural tendency of the host to mount an immune response against an administered protein is substantially reduced or eliminated. There are several examples where the administration of protein molecules offers therapeutic benefit. However the benefit is greatly reduced particularly where multiple doses of the therapeutic protein are required as the recipient immune system recognises and accelerates the elimination of the incoming therapeutic protein.

There are a number of therapeutic proteins whose therapeutic use is curtailed on account of their immunogenicity in man. For example, when murine antibodies are administered to patients who are not immunosuppressed, a majority of patients mount an immune reaction to the foreign material by making human anti-murine antibodies (HAMA). There are two serious consequences. First, the patient's anti-murine antibody may bind and clear the therapeutic antibody or immunoconjugate before it has a chance to bind to the tumour and perform its function. Second, the patient may develop an allergic sensitivity to the murine antibody and be at risk of anaphylactic shock upon any future exposure to murine immunoglobulin.

Several techniques have been employed to address the HAMA problem and thus enable the use in humans of therapeutic monoclonal antibodies (see, for example WO-A-8909622, EP-A-0239400, EP-A-0438310, WO-A-9109967). A common aspect of these methodologies has been the introduction into the therapeutic antibody, which in

general is of rodent origin, of significant tracts of sequence identical to that present in human antibody proteins. Such alterations are also usually coupled to alteration of particular single amino acid residues at positions considered critical to maintaining the antibody-antigen binding interaction. For antibodies, this process is possible owing to 5 the very high degree of structural (and functional) conservatism between antibody molecules of different species. However for potentially therapeutic proteins where no structural homologue may exist in the host species (e.g. human) for the therapeutic protein, such processes are not applicable. Furthermore, these methods have assumed that the general introduction of human sequence will render the re-modelled antibody 10 non-immunogenic. It is known however, that certain short peptide sequences ("T cell epitopes") can be released during the degradation of proteins within cells and subsequently presented by molecules of the major histocompatibility complex (MHC) in order to trigger the activation of T cells. For peptides presented by MHC class II, such activation of T cells can then give rise to an antibody response by direct 15 stimulation of B cells to produce such antibodies. None of the previous methods have addressed the elimination or avoidance of such epitopes in the final therapeutic molecule as a means to reduce or eliminate the antibody response against proteins. Nor have previous methods considered the elimination of peptides presented by MHC class I which can trigger a cytotoxic T cell response leading to cell killing. Such 20 killing of cells causes the release of cellular components including proteins which can, in turn, activate specialist cells which are highly active in protein processing and MHC presentation and also in release of inflammatory cytokines as a result of such activation. As a result, an inflammatory environment can be created which promotes the more active uptake and processing of the protein for therapeutic use thus 25 facilitating induction of an antibody response against the protein.

The elimination of T cell epitopes from proteins has been previously disclosed (see WO-A-9852976) whereby such potential T cell epitopes are defined as any peptide within the protein sequence with the ability to bind to MHC class II molecules. Such 30 potential epitopes are measured by any computational or physical method to establish

MHC binding. Implicit in the term "T cell epitope" is an epitope which is recognised by the T cell receptor and which can at least in principle cause the activation of these T cells. It is however usually understood that certain peptides which are found to bind to MHC class II molecules may be retained in a protein sequence because such 5 peptides are recognised as "self" within the organism into which the final protein is administered.

In practice, soluble proteins introduced into autologous organisms do sometimes trigger an immune response resulting in development of host antibodies which bind to 10 the soluble protein. One example is interferon alpha 2 to which a percentage of human patients make antibodies despite the fact that this protein is produced endogenously.

The present invention is based on the discovery by the inventors that MHC-binding 15 peptides within autologous proteins can trigger immune responses in live organisms to those proteins even when the specific protein is endogenously produced. A possible explanation for this is that the doses of such proteins administered are much higher than normal providing MHC-peptide formation which can activate T cells. Alternatively, the physiological environment into which such administered proteins 20 are presented is one favourable to efficient antigen processing and peptide-MHC formation at higher levels than usually encountered, for example in inflammatory situations.

According to a first aspect of the invention, there is provided a method of rendering a 25 protein, or part of a protein, non-immunogenic, or less immunogenic, to a given species, the method comprising:

- (a) determining at least part of the amino acid sequence of the protein;
- (b) identifying in the amino acid sequence one or more potential epitopes for T

cells ("T cell epitopes") which are found in an endogenous protein of the given species; and

- 5 (c) modifying the amino acid sequence to eliminate at least one of the T cell epitopes identified in step (b) thereby to reduce the immunogenicity of the protein or part thereof when exposed to the immune system of the given species.

The given species will usually be human. In step (c), one or more actual epitopes or potential epitopes may be eliminated.

10

Therefore, the present invention provides a modified method for creating proteins which trigger a reduced or absent immune response whereby one or more MHC binding peptides which are also found in the autologous organism's endogenous proteins are modified to reduce or eliminate binding to MHC molecules. Thus, in 15 practice, no assumption is made about which peptides might be tolerated by the organism (unless data is available which indicates that tolerance is in place). Overall, the invention encompasses the creation of protein molecules with reduced or absent immunogenicity in live organisms where one or more peptides which bind to MHC molecules are eliminated from the protein molecule. As such, the invention is an 20 improvement on the prior art which focuses only on the removal of potential T cell epitopes from proteins with the assumption that the organism is tolerant to self proteins or peptide sequences. In particular, the invention includes a range of human and non-human proteins which are modified by modification of one or more MHC binding peptides within the sequences. Such MHC binding peptides can include 25 peptides which bind to MHC class II molecules and/or peptides which bind to MHC class I.

The aspect of the invention described above is preferred to the alternative strategy of separately immunising the organism with such peptides in order to induce tolerance or

- the alternative of administering analogues or fragments of the protein which resist binding or uptake into cells (especially antigen-presenting cells), for example by elimination of the cell binding site in the protein. Tolerising the organism to the peptide in this way (*e.g.* the use of MHC binding peptides identified from a syngeneic
- 5 protein which can be used to induce tolerance in the host prior to administration of the entire protein) would require two therapeutic molecules, one to perform the main protein function and the other to induce the tolerance, which would not be favoured from the regulatory point of view.
- 10 Any method of identifying – in which term is included predicting – one or more potential T cell epitopes can be used in the invention. Acceptable methods may be computational or physical and include measuring of the binding of MHC-peptide complexes to T cell receptors, the testing of potential T cell epitopes in transgenic mice expressing human MHC molecules, the testing of potential T cell epitopes in
- 15 mice reconstituted with human antigen-presenting cells and T cells in place of their endogenous cells, and the testing of potential T cell epitopes for stimulation of T cells *in vitro* via presentation of peptides on MHC molecules using syngeneic antigen-presenting cells.
- 20 As well as identifying in the amino acid sequence one or more potential T cell epitopes which are found in an endogenous protein of the given species, a method of the invention may, and typically will, involve additionally identifying and eliminating one or more potential T cell epitopes which are *not* found in an endogenous protein of the given species, since such epitopes are even more likely to be immunogenic.
- 25 The present invention is based on a new concept in development of therapeutic proteins. It has been recognised previously that, with exogenous T cell dependent proteins, helper T cell epitopes are important to development of a significant immune response to the autologous protein. Such T cell epitopes function through the internal

processing of the protein releasing peptides which complex with MHC class II molecules and which are then presented on the surface of appropriate cells for potential binding to receptors on T cells. However, it is very difficult to predict which peptides within the protein will be processed appropriately such that MHC binding can occur and it is also a factor that many processed peptides will not bind to all allotypic variants of MHC class II molecules (MHC restriction). Furthermore, in any given living organism, it is difficult to predict whether a T cell response will actually be triggered by a given peptide presented on MHC class II because T cells may have been tolerised to such epitopes or may not have the repertoire of T cell receptors to bind to the MHC class II-peptide complex. Due to these complicating factors, it has previously been impractical to develop proteins with reduced or absent immunogenicity because of the difficulty in predicting actual T cell epitopes. The invention herein primarily takes the new approach of creating improved therapeutic proteins by removal of potential rather than actual T cell epitopes (usually defined by binding to MHC molecules) such that certain peptides within the molecule which are not actually immunogenic may be altered in addition to those immunogenic peptides. For a therapeutic molecule, preferably all of the potential T cell epitopes are removed whilst retaining activity of the protein. Preferably, this involves judicious choice of the amino acid substitutions enabling removal of the T cell epitopes and usually will involve the testing of a range of variant molecules with different amino acid substitutions.

Not all identified potential T cell epitopes which are found in an endogenous protein need be eliminated. For example, immune responses in general are not mounted to autologous circulating proteins, such as immunoglobulins and other serum proteins such as serum albumin. So potential T cell epitopes which are found for example in germline immunoglobulin variable region protein sequences of the given species (which will generally be human) may sometimes be ignored. However, an epitope considered as not generally available to the immune system to gain tolerance may be identified as a potential epitope for elimination according to the method of the present

invention. Examples of such include epitopes include those of intracellular proteins, such as nuclear proteins and integral membrane proteins.

The invention therefore provides proteins which have been altered to reduce their immunogenicity as well as a general method of altering such proteins to reduce their immunogenicity. A major principle of the present invention is that proteins are altered by identification of potential T cell epitopes and their subsequent alteration within the proteins in order to eliminate such potential epitopes. Optionally, epitopes recognised by host antibodies ("B cell epitopes") can also be removed if these can be identified for example with the aid of patient antisera or if the surface residues in a non-autologous protein can be altered to those of a related autologous protein endogenous to the host organism without losing all of the desired activity of the non-autologous molecule.

After elimination of one or more T cell epitopes, the protein may be tested for desired activity. It may retain its full activity, or it may retain a sufficient proportion of its original activity to be useful. In some circumstances, the activity may be altered either beneficially or at least in an acceptable way. Proteins entirely lacking in useful function post modification may be discarded.

Proteins of the present invention include those which have potential clinical use in humans or veterinary use in animals, especially where such uses involve multiple administrations of the proteins. They may be non-autologous or autologous. Proteins of the present invention include proteins with an enzymatic activity which has a beneficial therapeutic effect, proteins which are used to convert inactive drugs to active drugs within living organisms, proteins which are used to vaccinate whereby certain immunogenic epitopes are undesirable, proteins which perform as carriers of other molecules within the living organism and proteins which bind to other molecules within or introduced within the living organism in order to alter the biodistribution of the other molecules. Amongst the examples of non-autologous proteins with potential

benefit for *in vivo* human use are the following: Thrombolytic proteins streptokinase and staphylokinase; pro-drug activating enzymes such as asparaginase and carboxypeptidase G2; toxins of plant, fungal and bacterial origin such as ricin, saponin, pokeweed antiviral protein, mistletoe lectin, cholera toxin, pertussis toxin, 5 diphtheria toxin; bacterial phospholipase C (e.g. PE33, PE35, PE37, PE38, PE40); ribotoxins such as alpha-sarcin, clavin, mitogillin, restrictocin and bryodin-1 and 2. Other significant non-autologous molecules of proven and potential therapeutic benefit include streptavidin, cobra venom factor, insulin, collagen, non-autologous antibodies, non-autologous MHC molecules and non-autologous T cell receptor molecules.

10 Autologous proteins of proven and potential therapeutic value include IL-2, interferon α and β , granulocyte macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (GCSF), tissue plasminogen activator (t-PA), insulin, Factor VIII, Factor IX, erythropoietin (EPO), pituitary growth hormone and megakaryocyte growth and development factor (MGDF) and derivatives of these proteins produced by recombinant methods. Other examples of proteins include recombinant molecules derived or comprised of single or multiple domains from autologous or non-autologous proteins, recombinant proteins engineered to change or modify function or protein sequences derived from any of the above molecules.

15

20 A typical protocol within the general method of the present invention comprises the following steps:

I. Determining the amino acid sequence of the protein or a part thereof (if modification only of a part is required);

25 II. Identifying potential T cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the therapeutic protein, testing 30 of the protein or peptide parts thereof using transgenic animals with the MHC

molecules of the species to receive the therapeutic protein, or testing with transgenic animals reconstituted with immune system cells from the species to receive the therapeutic protein;

- 5 III. By genetic engineering or other methods for producing modified proteins, altering the protein to remove one or more of the potential T cell epitopes and producing such an altered protein for testing;
- 10 IV. (optionally) Within step III., altering the protein to remove one or more of the potential B cell epitopes;
- 15 V. Testing altered proteins with one or more potential T cell epitopes (and optionally B cell epitopes) removed in order to identify a modified protein which has retained all or part of its desired activity but which has lost one or more T cell epitopes.

Potential T-cell epitopes herein are defined as specific peptide sequences which either bind with reasonable efficiency to MHC class II molecules (or their equivalent in a non-human species), or which in the form of peptide:MHC complexes bind strongly to the T cell receptors from the species to receive the therapeutic protein or which, from previous or other studies, show the ability to stimulate T-cells via presentation on MHC class II. The method of the present invention recognises that an effective T cell-dependant immune response to a foreign protein requires activation of the cellular arm of the immune system. Such a response requires the uptake of the therapeutic (foreign) protein by antigen presenting cells (APCs). Once inside such cells, the protein is processed and fragments of the protein form a complex with MHC class II molecules and are presented at the cell surface. Should such a complex be recognised by binding of the T cell receptor from T-cells, such cells can be, under certain conditions, activated to produce stimulatory cytokines. The cytokines will elicit differentiation of B-cells to full antibody producing cells. In addition, such T cell

responses may also mediate other deleterious effects on the patient such as inflammation and possible allergic reaction.

It is understood that not all peptide sequences will be delivered into the correct MHC
5 class II cellular compartment for MHC class II binding or will be suitably released
form a larger cellular protein for subsequent MHC class II binding. It is further
understood that even such peptides which are presented by MHC class II on the
surface of APCs may not elicit a T-cell response for reasons including a lack of the
appropriate T-cell specificity, tolerance by the immune system to the particular peptide
10 sequence or the low affinity of the MHC-peptide complex for T cell receptor.

The present invention provides for removal of human (or other given species) potential
T-cell epitopes from the therapeutic protein whereby the primary sequence of the
therapeutic protein can be analysed for the presence of MHC class II binding motifs by
15 any suitable means. For example, a comparison may be made with databases of
MHC-binding motifs such as, by searching the "motifs" database at the world-wide
web site <http://wehih.wehi.edu.au/mhcpep/> (formerly wehil.wehi.edu.au or
wehi.wehi.edu.au). Alternatively, MHC class II binding peptides may be identified
20 using computational threading methods such as those devised by Altuvia *et al.* ((*J.
Mol. Biol.* **249** 244-250 (1995))). Similar methods may be used to identify and
remove epitopes which bind to MHC class I.

Having identified potential given species (*e.g.* human) T-cell epitopes, these epitopes
are then eliminated by alteration of one or more amino acids, as required to eliminate
25 the T-cell epitope. Usually this will involve alteration of one or more amino acids
within the T-cell epitope itself. This could involve altering an amino acid adjacent to
the epitope in terms of the primary structure of the protein or one which is not adjacent
in the primary structure but is adjacent in the secondary structure of the molecule. The
usual alteration contemplated will be amino acid substitution, but in certain
30 circumstances amino acid deletion or addition will be appropriate. In some instances,

selection of the appropriate amino acid substitution at any particular point in the therapeutic protein primary structure, can be made with reference to an homologous protein primary structure. This is particularly the case where a repertoire of homologous genes exist, as for example with immunoglobulins, or a single 5 homologous gene for the therapeutic protein exists, as is the case for the cobra venom factor protein and human complement factor C3 detailed in Example 1. However in other cases, there may not be an homologous protein to the therapeutic protein as is the case for potential therapeutics such as the thrombolytic agent staphylokinase. In such cases amino acids may be selected on the basis of similar size and/or charge, or more 10 preferably and where structural data for the protein exist in combination with or with reference to *in silico* protein modelling techniques. In some instances amino acid substitutions may be made to prevent proteolytic cleavage of a protein and thereby inhibit binding of a peptide to MHC class II. Examples of protease cleavage sites include those reported by van Noort & van der Drift (*J. Biol. Chem.* **264** 14159-14164 15 (1989)) and van Noort *et al* (*Eur. J. Immunol.* **21** 1989-1996 (1991)). Examples of amino acids which prevent protease digestion have been identified e.g. Kropshofer *et al.*, *J. Immunol.* **151** 4732-4742 (1993).

In the method of the present invention, usually a number of variants of altered proteins 20 will be produced and tested for retention of the desired activity. Where it is desirable to maximise the removal of potential T cell epitopes from the protein, it will be common to create a range of variants including some with potential T cell epitopes remaining in the molecule. It will be recognised that with certain protein molecules, it is difficult to radically alter the molecule and to retain full activity and so judicious use 25 of molecular modelling of variants and the testing of a maximum number of variants is desirable. For molecular modelling, standard commercially available software packages can be used to model the protein structure using as starting point either of a crystal structure or a model built from homology or protein folding prediction. Information on parts of the protein involved in imparting the molecule with its activity 30 will assist in modelling variants enabling best choice of altered amino acids which

remove a potential T cell epitope (or optional B cell epitope) whilst retaining activity.

In the method of the present invention where a number of variants of altered proteins will be produced and tested for retention of the desired activity, it is desirable to have
5 a high-throughput method for screening large numbers of variants. Such methods include *in vivo* methods for expression of gene variants in cells such as bacteria with rapid isolation of the proteins for example using an antibody to a conserved region of the proteins, or via a protein purification tag included in the protein sequence. As an alternative, *in vitro* methods such as *in vitro* transcription and translation can be used
10 in some cases. Where the protein binds to another molecule, display methods such as phage display and ribosome display can be used in order to select out variants which retain binding activity.

In the practice of the present invention, specific amino acid alterations can be
15 conducted by recombinant DNA technology, so that the final molecule may be prepared by expression from a recombinant host using established methods. However, the use of protein chemistry or any other means of molecular alteration is not excluded in the practice of the invention. Whilst the present invention provides a method for removal of potential T cell epitopes (and optional B cell epitopes) from protein
20 molecules, the method does not exclude testing of variant molecules produced within the invention for actual T cell epitope activity including testing of the protein or peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the therapeutic protein, or testing with transgenic animals reconstituted with immune system cells from the species to receive the therapeutic protein.

25 Whilst such methods are not yet routine, *in vitro* T cell assays can be undertaken whereby the protein can be processed and presented on MHC class II by appropriate antigen-presenting cells (APCs) to syngeneic T cells. T cell responses can be measured by simple proliferation measurements (especially if the APCs have been
30 irradiated or otherwise treated to prevent proliferation) or by measuring specific

cytokine release. In order to account for different MHC class II allotypes, a range of *in vivo* assays will usually be required in order to broadly test for T cell epitopes. Alternatively, transgenic animals equipped with human (or the desired species) MHC class II molecules could be used to test for T cell epitopes especially where the host 5 MHC class II repertoire has been removed and especially where one or more other host accessory molecules in APC/T cell interaction have also been replaced with human (or the desired species) such as CD4 on T cells.

In a further aspect, the invention provides molecules resulting from method as 10 described above. Such molecules may be useful for treating or preventing a disease or condition. The invention also extends to the use of such molecules in *in vivo* and *in vitro* diagnosis and for human or veterinary use. Preferred features of each aspect of the invention are as for each other aspect, *mutatis mutandis*.

15 The invention is illustrated but not limited by the following examples. The examples refer to the following figures:

FIGURE 1 shows the protein sequence of mature cobra venom factor;

20 FIGURE 2 shows the protein sequence of an altered cobra venom factor - chain;

FIGURE 3 shows the protein sequence of an altered cobra venom factor - chain;

25 FIGURE 4 shows the protein sequence of an altered cobra venom factor - chain;

30 FIGURE 5 shows the protein sequence of streptokinase from *Streptococcus equisimilis*;

FIGURE 6 shows the protein sequence of an altered streptokinase molecule;

FIGURE 7 shows the protein sequence of mature staphylokinase;

5

FIGURE 8 shows the protein sequence of an altered staphylokinase molecule;

FIGURE 9 shows the protein sequence of wild-type bryodin 1;

10

FIGURE 10 shows the protein sequence of an altered bryodin 1 molecule;

FIGURE 11 shows the protein sequence of mature human interferon 2 ; and

15

FIGURE 12 shows the protein sequence of an altered human interferon 2
molecule.

Example 1

In the present example the cobra venom factor (CVF) protein is analysed for the presence of potential MHC binding motifs and a method disclosed for the removal of a number of these from the molecule.

CVF is the non-toxic complement-activating glycoprotein in cobra venom. The mature CVF protein consists of three polypeptide chains α , β and γ , produced by post-translational processing of a pre-pro protein of approximate molecular weight 150kDa (Fritzinger D.C. *et al.*, *Proc. Nat'l. Acad. Sci. USA* 91 12775-12779 (1994)). The α and β chains are both linked to the γ chain via single disulphide bridges. In addition, both the α chain and the γ chain have single intra chain disulphide bonds whilst the β chain has a complex arrangement of six further internal disulphide bonds. The mature protein has four potential sites for N-glycosylation of which only three are used

(Vogel, C.W & Muller-Eberhard *J. Immunol.* **18** 125-133 (1984)).

In the preferred embodiment of the present invention, production of the reduced immunogenicity or altered version of the therapeutic protein is by recombinant DNA technology. For the present example, it is understood that the expedient of recombinant production of the mature CVF protein alone is likely to provide a considerable reduction in immunogenicity of the protein. This assertion stems from the knowledge that a degree of the immunogenicity arising from administration of CVF purified from *Naja naja* venom, arises from antibody responses to the particular pattern of glycosylation not encountered in mammalian proteins (Gowda, D.C *et al.*, *J. Immunol.* **152** 2977-2986 (1994)). It is also understood that deglycosylated and also sialylated CVF that would arise from recombinant production of CVF, for example in a mammalian producer cell system, have equal functional activity with native mature CVF (Gowda, D.C *et al.* (1994) *ibid.*).

15

In humans CVF triggers the alternative (properdin) pathway of complement activation. CVF forms a bimolecular complex with factor B which is cleaved by factor D into Bb which remains bound to CVF to form the C3/C5 convertase CVF,Bb. This complex is functionally and structurally analogous to the human C3/C5 convertase formed during the activation of the alternative pathway. The clinical importance of CVF lies in the high relative stability of the CVF,Bb complex versus the native C3/C5convertase ($t_{1/2}$ of 7 hours versus $t_{1/2}$ of 90 seconds) and in particular, the inability of CVF,Bb to be disrupted and hence down regulated by factors H and I (Gowda, D.C *et al.*, (1994) *ibid.*). The net result of CVF administration therefore is to lead to the depletion of complement in human serum by continuous efficient and uncontrolled complement activation.

This property has been exploited as a research tool for *in vivo* and *in vitro* de-complementation (Cochrane C.G *et al.*, *J. Immunol.* **105** 55 (1970)) and has also been exploited for the selective elimination of tumour cells as a conjugate with a tumour

targeting monoclonal antibody (Vogel, C.-W. & Muller-Eberhard H.J. *Proc. Nat'l Acad. Sci. USA* **78** 7707 (1981)). Availability of a non-immunogenic CVF would have considerable importance as a potential therapeutic agent for the depletion of complement in the plasma of patients undergoing organ xenotransplantation or in the
5 construction of second generation antibody conjugates for targeted activation of complement in cancer patients.

Method for identification of potential MHC class II binding motifs in cobra Venom Factor:

10 The sequence of CVF was identified from the GenBank database. The sequence with accession number U09969 was used throughout. The protein sequences of the mature α , β and γ chains were identified (Figure 1) and analysed individually for the presence of potential MHC class II binding motifs. Analysis was conducted by computer aided comparison to a database of MHC-binding motifs as resident on world wide web site
15 <http://wehih.wehi.edu.au/mhcpep/>.

Results of the "searching" process on the α chain, indicate the presence of 638 potential MHC class II binding motifs. Of these, 525 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences.
20 These epitopes were not considered further on the basis that immune responses in general are not mounted to autologous circulating proteins such as immunoglobulins. This implies immunological tolerance to the potential T-cell epitopes present in the structure of the immunoglobulins (and indeed the majority of human proteins). Epitopes presented by non-autologous proteins such as CVF which are identical or
25 similar to motifs present in immunoglobulin proteins are likely also to be tolerated and in practice may be retained through the de-immunisation process.

Following subtraction of the human immunoglobulin protein germline motifs, the remaining 113 potential epitopes in the α chain, were analysed individually for

similarity to non-immunoglobulin protein sequences. In practice, predicted anchor residues for each potential epitope were used in a consensus sequence search of human expressed proteins. The SwissProt and GenBank translated sequence databases were interrogated using commercially available software (DNAstar Madison, WI, USA).

5 Epitopes identified in known circulating human proteins were not considered further and were therefore allowed to remain unchanged within the CVF α chain. An example of one such rejected potential epitope is given by the sequence FKPGMPY at positions 332-338 in the CVF α chain (numbering from first amino acid of the mature α chain). This sequence represents a predicted consensus binding motif for HLA-DRQB1*0301 with anchor residues underlined. Database searching using the consensus sequence FxxxMxY identifies only a single entry in a human protein subset of the SwissProt database corresponding to human serum biotinidase (SwissProt accession # A54362). An example of an epitope where no match to a human protein considered to be in the general circulation was found is provided by sequence

10 YYQVGNNEI at position 501-509 in the CVF α chain. This sequence represents a potential epitope for presentation by HLA-DRB1*0101. Consensus sequence searching identifies only four human proteins containing this motif, of which three are nuclear proteins of differentiated tissues such as brain, and the fourth is an integral membrane protein. These may be considered as not generally available to the immune

15 system to gain tolerance and therefore identify this as a potential epitope for elimination according to the method of the present invention. Similarly, a further potential HLA-DR1 binding motif was identified in the α chain. Peptide sequence YVVVQVTGP at positions 81-89. This motif identifies a single human nuclear protein DNA polymerase alpha (GenBank accession # M64481), in the same data set

20 and was also therefore identified for modification by the method of the present invention. Following these processes, a total of 15 potential epitopes in the α chain were considered for removal by amino acid substitution.

25

Results of the "searching" process on the β chain, indicate the presence of 366

potential MHC class II binding motifs. Of these, 281 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences and were not considered further. Following a second round of subtractions using a database of human serum protein sequences (as above), 18 potential epitopes were
5 considered for removal.

Results of the "searching" process on the γ chain, indicate the presence of 267 potential MHC class II binding motifs. Of these, 219 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences and
10 were not considered further. Following a second round of subtractions using a data base of human serum protein sequences (as above), 9 potential epitopes were considered for removal.

The net result of these processes was to identify those residues within the CVF
15 molecule which should be altered to eliminate potential MHC class II binding motifs. Individual amino acids within the predicted binding motifs were selected for alteration. With the object of maximising the likelihood of maintaining protein functional activity, in all cases conservative amino acid substitutions were chosen at any given site. In many cases, individual amino acid or even short strings (<5
20 consecutive residues) were substituted by reference to the published sequence of human complement factor 3 (C3) (GenBank accession # K02765) which shows areas of strong homology, including regions of identity, with CVF. In two instances, potential epitopes were eliminated from the β chain by insertion of additional amino acids. Amino acids were selected with reference to the human C3 protein.

25

Altered CVF α chain, β chain and γ chain sequences were compiled (Figures 2 to 4) and further analysed by database comparison, as previously, for confirmation of successful elimination of potential MHC class II binding motifs.

Method for construction of altered CVF molecules:

PCR primers CVF1for; 5'ATAAGAATGCGGCCGCATGGAGAGGATGGCTCTCT and CVF1rev; 5'ATAAGAATGCGGCCGCTATCATTGATTCTTCTGAAC were used to amplify a 4985bp fragment from a λgt11 cobra venom gland cDNA library (Fritzinger DC *et al.*, *ibid.*). The PCR was conducted on a total library DNA preparation using high fidelity polymerase mix optimised for long distance PCR (*Advantage PCR Kit*, Clontech, Basingstoke, UK) and conditions suggested by the supplier. The PCR product was cloned into pcDNA3.1 (Invitrogen, Leek, The Netherlands) as a *NotI* restriction fragment using standard techniques (Sambrook J., Fritsch E.F. & Maniatis T. (eds.) in: Molecular Cloning a Laboratory Manual, Cold Spring Harbor Laboratory Press, NY, USA (1989)). The gene sequence was confirmed to be identical to database entries using commercially available reagent systems and instructions provided by the supplier (Amersham, Little Chalfont, UK). Site directed mutagenesis was conducted using synthetic oligonucleotides and the “quick-change” procedure and reagents from Stratagene (Cambridge, UK). Mutated (de-immunised) versions of the gene were confirmed by sequencing. Mutated CVF genes were transfected into CHO cells by electroporation. Stable transfectants were selected using G418, and clones secreting active CVF were selected using a C consumption assay (Gowda D.C *et al.* (1994) *ibid.*; Cochrane C.G. et al (1970) *ibid.*) Expressing clones were expanded and recombinant protein was purified from the culture supernatant using sequential column chromatography and methods as described (Vogel C-W *et al.*, *J. Immunological Methods* 73 203-220 (1984)).

Example 2

The present invention details a process whereby potentially immunogenic epitopes within a non-autologous protein may be identified and offers methodology whereby such epitopes may be eliminated. It is understood that there are a number of proven therapeutic proteins for which their therapeutic use is curtailed on account of their immunogenicity in man. In the present example the therapeutic protein streptokinase

is analysed for the presence of potential MHC binding motifs and a method disclosed for the removal of a number of these from the molecule.

Streptokinase (SK) is a single chain protein of approximate molecular weight 47kDa
5 that is produced by certain strains of β -haemolytic streptococci (Huang T.T. *et al.*, *Mol. Biol.* **2** 197-205 (1989)). The protein has no inherent enzymatic activity but has considerable clinical importance owing to its ability to efficiently bind human plasminogen, potentiating its activation to plasmin and thereby promoting the dissolution of fibrin filaments in blood clots. Several studies have shown that SK is an
10 effective thrombolytic agent in the treatment of coronary thrombosis, improving survival (ISIS-2 Collaborative Group, *Lancet* **2** 349-360 (1988)) and preserving left ventricular function following myocardial infarction (ISAM Study Group, *N. Engl. J. Med.* **314** 1465-1471 (1986); Kennedy J.W. *et al.*, *Circulation* **77** 345-352 (1988)). Despite the undoubtedly therapeutic value of SK, the non-autologous origin of the
15 protein is disadvantageous due to its immunogenicity in humans. The production of neutralising antibodies in the patient generally limits the protein to a single use.

Method for identification of potential MHC class II binding motifs in streptokinase:

20 The sequence of streptokinase was identified from the GenBank database. The sequence with accession number S46536 was used throughout (Figure 5). The sequence was analysed for the presence of potential MHC class II binding motifs by computer aided comparison to a database of MHC-binding motifs as resident on world wide web site <http://wehih.wehi.edu.au/mhcpep/>.

25 Results of the "searching" process indicate the presence of 395 potential MHC class II binding motifs. Of these, 283 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences. These epitopes were not considered further on the basis that immune responses in general are not mounted to

autologous circulating proteins such as immunoglobulins. This implies immunological tolerance to the potential T-cell epitopes present in the structure of the immunoglobulins (and indeed the majority of human proteins). Epitopes presented by non-autologous proteins such as SK which are identical or similar to motifs present in immunoglobulin proteins are likely also to be tolerated and in practice may be retained through the de-immunisation process.

Following subtraction of the human immunoglobulin protein germline motifs, the remaining 112 potential epitopes were analysed individually for similarity to non-immunoglobulin protein sequences. In practice, predicted anchor residues for each potential epitope were used in a consensus sequence search of human expressed proteins. The SwissProt and GenBank translated sequence databases were interrogated using commercially available software (DNAstar Madison, WI, USA). Epitopes identified in known circulating human proteins were not considered further and were therefore allowed to remain unchanged within the SK molecule. An example of one such rejected potential epitope is given by the sequence LLKAIQEQL at positions 79-87 in the SK protein. This sequence represents a predicted consensus binding motif for HLA-DR1*0101 with anchor residues underlined. Database searching using the consensus sequence LxxAxxxxL identifies >4000 entries in a human protein sub-set of the SwissProt database, including serum albumin protein (SwissProt accession number P02768). An example of an epitope where no match to a human protein considered to be in the general circulation was found is provided by sequence YVDVNTN at position 299-305 in the SK protein. This sequence represents a potential epitope for presentation by HLA-DR4*0401. Consensus sequence searching identifies < 50 human proteins containing this motif, of which many are intracellular proteins of differentiated tissues such as brain. These may be considered as not generally available to the immune system to gain tolerance and therefore identify this as a potential epitope for elimination according to the method of the present invention. Similarly, a further potential HLA-DR1*0101 binding motif was identified in the SK peptide sequence KADLLKAI at positions 76-83 of the SK

protein. This motif identifies < 150 human proteins in the same data set and was also identified for modification by the method of the present invention.

The net result of these processes was to identify those residues within the SK molecule
5 which should be altered to eliminate potential MHC class II binding motifs. Individual amino acids within the predicted binding motifs were selected for alteration. With the object of maximising the likelihood of maintaining protein functional activity, in all cases conservative amino acid substitutions were chosen at any given site. A new (de-immunised) SK sequence was compiled (Figure 6) and
10 further analysed by database comparison, as previously, for confirmation of successful elimination of potential MHC class II binding motifs.

Method for construction of de-immunised SK molecules:

PCR primers SK1 (5'-ggaattcatgattgtggacctgagttggctg) and SK2 (5'-
15 tggatccttatttcgttaggtatc) were used to amplify the wild-type SK gene from a strain of *Streptococcus equisimilis* group C (ATCC accession number 9542). The resulting 1233bp fragment was cloned into pUC19 as a *Bam*HI-*Eco*RI restriction fragment using standard techniques (Sambrook J., Fritisch E.F. & Maniatis T. (eds.) in: Molecular Cloning a Laboratory Manual, Cold Spring Harbor Laboratory Press, NY, USA (1989)). The gene sequence was confirmed to be identical to database entries using commercially available reagent systems and instructions provided by the supplier (Amersham, Little Chalfont, UK). Site-directed mutagenesis was conducted using synthetic oligonucleotides and the "quick-change" procedure and reagents from Stratagene UK Ltd. Mutated (de-immunised) versions of the gene were confirmed by
20 sequencing. Mutated SK genes were sub-cloned as *Eco*RI-*Bam*HI fragments into the bacterial expression vector pEKG-3 (Estrada M.P. et al., *Bio/Technology* 10 1138-1142 (1992)) for expression of de-immunised SK. Recombinant protein was purified using a plasminogen affinity column according to the method of Rodriguez et al. (Rodriguez P. et al., *Biotechniques* 7 638-641 (1992)). Fibrinolytic activity was
25 assessed using the casein/plasminogen plate technique and the *in vitro* clot lysis assay
30

as described by Estrada *et al.* (Estrada *et al.*, *ibid.*).

Example 3

In the present example staphylokinase is analysed for the presence of potential MHC
5 binding motifs and a method disclosed for the removal of a number of these from the
molecule.

Staphylokinase protein from *Staphylococcus aureus* has recognised and well
characterised profibrinolytic properties. Recombinant forms of the protein have been
10 previously produced and *in vitro* and *in vivo* studies have indicated that the protein
holds considerable promise for thrombolytic therapy (Sako, T., *Eur. J. Biochem.* **149**
557-563 (1985); Schlott, B. *et al.*, *Biotechnology* **12** 185-189 (1994); Collen, D. *et al.*,
15 *Circulation* **94** 197-462 (1996)). However, clinical use in humans has been limited
due to the demonstrated immunogenicity of the protein in man (Collen, D. *et al.*,
15 *Circulation* **95** 463-472 (1997)). Availability of a non-immunogenic staphylokinase
would have considerable importance as a potential agent for thrombolytic therapy.

The mature staphylokinase protein consists of a single polypeptide chain of 137 amino
acids with approximate molecular weight 15.4kDa (Silence K. *et al.*, *J Biol.*
20 *Chemistry*, **270** 27192-27198 (1995)).

**Method for identification of potential MHC class II binding motifs in
staphylokinase:**

The sequence of staphylokinase (sakSTAR) protein as given in table 1 of Collen *et al.*
25 (Collen, D *et al.* (1996) *ibid.*) was used throughout. The protein sequences of the
mature staphylokinase (Figure 7) were analysed for the presence of potential MHC
class II binding motifs. Analysis was conducted by computer aided comparison to a
database of MHC-binding motifs as resident on world wide web site
<http://wehih.wehi.edu.au/mhcpep/>.

Results of the "searching" process indicate the presence of 128 potential MHC class II binding motifs. Of these, 91 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences. These epitopes were not considered further. Epitopes presented by non-autologous proteins such as 5 staphylokinase which are identical or similar to motifs present in immunoglobulin proteins are likely to be tolerated and in practice may be retained through the de-immunisation process.

Following subtraction of the human immunoglobulin protein germline motifs, the 10 remaining 37 potential epitopes were analysed individually for similarity to non-immunoglobulin protein sequences. In practice, predicted anchor residues for each potential epitope were used in a consensus sequence search of human expressed proteins. The SwissProt and GenBank translated sequence databases were interrogated using commercially available software (DNAstar Madison, WI, USA). 15 Epitopes identified in known circulating human proteins were not considered further and were therefore allowed to remain unchanged within the protein.

The net result of these processes was to identify those residues within the 20 staphylokinase molecule which should be altered to eliminate potential MHC class II binding motifs. Individual amino acids within the predicted binding motifs were selected for alteration. With the object of maximising the likelihood of maintaining protein functional activity, in all cases conservative amino acid substitutions were chosen at any given site.

25 An altered staphylokinase sequence was compiled (Figure 8) and further analysed by database comparison, as previously, for confirmation of successful elimination of potential MHC class II binding motifs.

Method for construction of altered staphylokinase molecules:

30 A wild-type staphylokinase gene was synthesised under contract by Genosys

Biotechnologies Ltd (Cambridge, UK). The gene was constructed by PCR using long (80-mer) overlapping synthetic primers and the sequence as given by Collen, D *et al.* (Collen, D. *et al.*, (1996) *ibid.*) The synthetic gene was cloned as a 453 bp *Eco*RI-*Hind*III restriction fragment into bacterial expression vector pMEX (MoBiTec, 5 Gottingen, Germany). The gene sequence was confirmed to be identical to database entries using commercially available reagent systems and instructions provided by the supplier (Amersham, Little Chalfont, UK). Altered (reduced immunogenicity) versions of the gene were engineered using site directed mutagenesis of the wild-type gene in pMEX. Short (18-mer) synthetic oligonucleotides and the "quick-change" 10 procedure and reagents from Stratagene (Cambridge, UK) were used to create the variant genes. All variant gene sequences were confirmed by DNA sequencing.

Mutated staphylokinase genes were transformed into *E. coli* strain TG1 by standard techniques. A single transformed clone was selected and clones secreting active 15 staphylokinase were selected using a fibrin plate assay (Astrup, T. *et al.*, *Arch. Biochem. Biophys.* 40: 346-351 (1952); Collen, D. *et al.*, *Fibrinolysis* 6: 203-213 (1992)). The best expressing clone was grown up and recombinant protein was purified from the culture supernatant using sequential column chromatography and methods as described previously (Collen, D. *et al.*, (1992) *ibid.*; Schlott *et al.*, *ibid.*). 20

Example 4

In the present example bryodin 1 is analysed for the presence of potential MHC binding motifs and a method disclosed for the removal of a number of these from the molecule.

The gene for bryodin 1 protein has recently been cloned from *Bryonia dionia*, a member of the *Cucurbitaceae* family of plants (Gawlak, S. *et al.*, *Biochemistry* 36 3095-3103 (1997)). Bryodin 1 is a type 1 ribosome inactivating protein. Studies using recombinant forms of the protein have indicated that bryodin 1 holds considerable 30 promise for immunotoxin therapy for cancer and other diseases (Gawlak, S. *et al.*,

(1997) *ibid.*). However, clinical use in humans as with other immunotoxin agents, is likely to be curtailed due to immunogenicity of the protein in man. Availability of a non-immunogenic bryodin would have considerable importance as a potential component in immunotoxin based therapies.

5

The mature bryodin protein consists of a single polypeptide chain of 267 amino acids with approximate molecular weight 29kDa. The wild-type sequence is illustrated in Figure 9.

10

Method for identification of potential MHC class II binding motifs in bryodin 1:

The sequence of bryodin 1 protein as given by Gawlak *et al.*, (Gawlak, S. *et al.*, (1997) *ibid.*) was used throughout. The protein sequence of the mature bryodin 1 (Figure 9) was analysed for the presence of potential MHC class II binding motifs. Analysis was conducted by computer aided comparison to a database of MHC-binding motifs as resident on world wide web site <http://wehih.wehi.edu.au/mhcpep/>.

15

Results of the "searching" process indicate the presence of 315 potential MHC class II binding motifs. Of these, 259 matched sequences identified in a database of human germline immunoglobulin variable region protein sequences. These epitopes were not considered further.

20

Following subtraction of the human immunoglobulin protein germline motifs, the remaining 56 potential epitopes were analysed individually for similarity to non-immunoglobulin protein sequences. The predicted anchor residues for each potential epitope were used in a consensus sequence search of human expressed proteins. The SwissProt and GenBank translated sequence databases were interrogated using commercially available software (DNAstar Madison, WI, USA). Epitopes identified in known circulating human proteins were not considered further and were therefore allowed to remain unchanged within the protein.

25

30

The net result of these processes was to identify those residues within the bryodin 1 molecule which should be altered to eliminate potential MHC class II binding motifs. For bryodin 1 protein, 13 potential epitopes were identified for elimination from the molecule. Individual amino acids within the predicted binding motifs were selected 5 for alteration. With the object of maximising the likelihood of maintaining protein functional activity, in all cases conservative amino acid substitutions were chosen at any given site.

An altered bryodin 1 sequence was compiled (Figure 10) and further analysed by 10 database comparison, as previously, for confirmation of successful elimination of potential MHC class II binding motifs.

Method for construction of altered bryodin 1 molecules:

A wild-type bryodin 1 gene was synthesised under contract by Genosys 15 Biotechnologies Ltd (Cambridge, UK). The gene was constructed by PCR using long (80-mer) overlapping synthetic primers and the sequence as given by Gawlak *et al.*, (Gawlak, S. *et al.*, (1997) *ibid.*). The synthetic gene was cloned as a 843bp *NcoI*-*EcoRI* restriction fragment into a modified version of bacterial expression vector pET22b+ (Novagen, Madison, USA). The vector was modified to remove the *pelB* 20 leader sequence which was previously shown to impede efficient expression of the bryodin 1 protein (Gawlak, S. *et al.*, (1997) *ibid.*). The modification was conducted by digestion with *XbaI* and *NcoI* to remove 107bp of DNA encompassing the *pelB* leader sequence. Elements of non-*pelB* sequence including the ribosome binding site 25 sequence and the *NcoI* site, were restored in the vector by ligation of a linker molecule to the *XbaI/NcoI* free ends in the vector. The linker was formed by annealing complementary oligonucleotides:

L1f (5'-ctagaataatttgttaactttaagaaggagatatacatatgcc) and
L1r (5'-ccatggatatgtatatctccttctaaagttaaacaaaatttt).

- Oligonucleotides were supplied with phosphorylated ends by Genosys Biotechnologies Ltd (Cambridge, UK). Restriction digests, DNA purification, ligation reactions *etc.* were conducted using standard procedures and conditions recommended by the reagent suppliers. Altered (reduced immunogenicity) versions of the gene were 5 engineered using site directed mutagenesis of the wild-type gene in the modified pET22b vector. Short (18-mer) synthetic oligonucleotides and the "quick-change" procedure and reagents from Stratagene (Cambridge, UK) were used to create the variant genes. All variant gene sequences were confirmed by DNA sequencing.
- 10 Wild-type and mutated bryodin 1 gene variants were transformed into *E. coli* strain TG1 by standard techniques. A single transformed clone was selected for each gene and this clone used for sequence analysis. For expression work, bryodin 1 genes were transformed into *E. coli* strain BL21(λDE3) obtained from the ATCC. Recombinant bryodin 1 and variant bryodin 1 proteins were purified using methods described 15 previously (Gawlak, S. *et al.*, (1997) *ibid.*). Following re-folding of the crude protein from inclusion bodies, purified bryodin 1 and variants were obtained > 95% pure using CM-Sepharose chromatography as previously (Gawlak, S. *et al.*, (1997) *ibid.*). Activity of the recombinant proteins was assessed using a cell-free protein synthesis inhibition assay and methods according to Siegall *et al.*, (Siegall, C.B. *et al.*, 20 *Bioconjugate Chem.* 5 423-429 (1994)).

Example 5

In the present example the human interferon α2 protein is analysed for the presence of potential MHC binding motifs and a method disclosed for the removal of a number of 25 these from the molecule.

Interferon alpha 2 (INA2) is an important glycoprotein cytokine expressed by activated macrophages. The protein has antiviral activity and stimulates the production of at least two enzymes; a protein kinase and an oligoadenylate synthetase,

on binding to the interferon alpha receptor in expressing cells. The mature INA2 protein is single polypeptide of 165 amino acids produced by post-translational processing of a 188 amino acid pre-cursor protein by cleavage of a 23 amino acid signal sequence from the amino terminus.

5

The protein has considerable clinical importance as a broad spectrum anti-viral, anti-proliferative and immunomodulating agent. Recombinant and other preparations of INA2 have been used therapeutically in a variety of cancer and viral indications in man (reviewed in Sen, G.G. and Lengyel P, *J. Biol. Chem.* **267** 5017-5020 (1992)).

10

However despite very significant therapeutic benefit to large numbers of patients, resistance to therapy in certain patients has been documented and one important mechanism of resistance has been shown to be the development of neutralising antibodies detectable in the serum of treated patients (Quesada, J.R. *et al.*, *J. Clin. Oncology* **3** 1522-1528 (1985); Stein R.G. *et al.*, *New Eng. J. Med.* **318** 1409-1413 (1988); Russo, D. *et al.*, *Br. J. Haem.* **94** 300-305 (1996); Brooks M.G. *et al.*, *Gut* **30** 1116-1122 (1989)). An immune response in these patients is mounted to the therapeutic interferon despite the fact that a molecule of at least identical primary structure is produced endogenously in man. In the present example, an interferon alpha 2 molecule with reduced potential immunogenicity in man is presented.

20

Method for identification of potential MHC class II binding motifs in human interferon alpha 2:

25

The sequence of INF2 was identified from the GenBank database. The sequence with accession number P01563 was used throughout. The protein sequences of the mature INF2 protein was identified and the sequence excluding the first 23 amino acid signal peptide analysed for the presence of potential MHC class II binding motifs (Figure 11). Analysis was conducted by computer using MPT ver1.0 software (Biovation, Aberdeen, UK). This software package conducts "peptide threading" according to the methods disclosed in WO-A-9859244. The software is able to provide an index of potential peptide binding to 18 different MHC class II DR alleles covering greater than

96% of the HLA-DR allotypes extant in the human population.

Results of the “peptide threading” process on the INF2, indicate the presence of a total of 18 individual potential epitopes. The epitopes map to five distinct clusters of 5 overlapping epitopes encompassing residues 7-40 (cluster 1), residues 45-70 (cluster 2), residues 79-103 (cluster 3), residues 108-132 (cluster 4) and residues 140-163 (cluster 5). Each of the five clusters contain 5, 3, 4, 3 and 3 potential epitopes respectively.

10 In order to prioritise epitopes for removal, the epitope clusters were then mapped to the known structure-function features on the molecule. For INF2 evidence from homology modelling (Murgolo N.J. *et al.*, *Proteins: Structure, Function & Genetics* **17** 62-74 (1993)), site directed mutagenesis (Tymms, M.J. *et al.*, *Antiviral Res.* **12** 37-48 (1989); McInnes B. *et al.*, *J. Interferon Res.* **9** 305-314 (1989)), cross-species 15 chimaeric molecules (Ra, N.B.K. *et al.*, *J. Biol. Chem.* **263** 8943-8952 (1988); Shafferman, A. *et al.* *J. Biol. Chem.* **262** 6227-6237 (1987)), deletion mutants (Wetzel, R. *et al.*, In: *Interferons* New York Academic Press, pp819-823 (1982)) and serological mapping studies (Lydon N.B. *et al.*, *Biochemistry* **24** 4131-4141 (1985); Trotta P.P. *et al.*, In: *The Interferon System* Dianzani F & Rossi G.B (eds.) New York, 20 Raven Press, 1985 pp231-235), suggest epitopes in clusters 1 and 2 are the highest priority targets for removal. With reference to the structural model of Murgolo et al (Murgolo N.J. et al (1993) *ibid.*), cluster 1 featuring 5 potential epitopes encompasses the functionally important helix A and the AB surface loop region of the INF2 molecule. This region is important for the antiviral activity and is involved in binding 25 to the human INF2 receptor structure. Most significantly, epitopes for neutralising antibodies have been mapped to this region, specifically residues 10-11 of the helix A structural element (Lydon N.B. *et al.*, (1985) *ibid.*).

On this basis, cluster 1 epitopes at positions 7-19 and 13-25 were eliminated by 30 substitution of threonine for leucine at position 15 (L₁₅T using single letter codes).

This procedure was conducted interactively *in silico* using the MPTver1 package. Similarly, cluster 1 epitope at position 28-41 was eliminated by substitution F₂₇Y. This latter substitution had the concomitant effect of reducing the number of potential binding alleles for the overlapping epitope at position 22-34 from 13 to 11.

5

- Cluster 2 epitopes extend from the AB loop through the helix B region and into the BC loop domain. Neutralising antibodies have been shown to bind in the BC loop (Lydon N.B. *et al.*, (1985) *ibid.*; Trotta P.P. *et al.*, (1985) *ibid.*) therefore cluster 2 epitope at position 58-70 was also targeted for removal. Substitution N₆₅L reduces potential immunogenicity in this region by eliminating 3 overlapping epitopes encompassing positions 61-77, which collectively are predicted to bind 5 different MHC DR alleles. Additionally, this substitution also reduces the number of different binding alleles at epitope 58-70 from 5 to 3.
- 10 Other epitope clusters (e.g. 3-5) map to either buried regions of the molecule or surface regions not involved in receptor binding and hence provide antigenic sites to which antibody responses are largely non neutralising.
- 15 Other epitope clusters (e.g. 3-5) map to either buried regions of the molecule or surface regions not involved in receptor binding and hence provide antigenic sites to which antibody responses are largely non neutralising.
- 20 Using the above method, an altered INF2 protein sequence was compiled containing 3 substitutions from the starting sequence and is depicted in Figure 12. This sequence is predicted to be significantly less immunogenic with respect to human MHC class II presentation. The areas of reduced immunogenicity focussed to regions of the molecule where antibody mediated neutralisation of the protein has been shown to occur with the potential to limit the clinical efficacy of the molecule as a therapeutic entity.
- 25

Method for construction of altered interferon alpha 2 molecule:

- A wild-type INA2 gene was synthesised under contract by Genosys Biotechnologies
30 Ltd (Cambridge, UK). The gene was constructed by PCR using long (80-mer)

overlapping synthetic DNA primers and the sequence given in GenBank accession number M29883. The synthetic gene was cloned as a 520bp *Eco*RI-*Hind*III restriction fragment into bacterial expression vector pMEX8 (MoBiTec, Gottingen, Germany). The gene sequence was confirmed to be identical to the desired gene using commercially available reagent systems and instructions provided by the supplier (Amersham, Little Chalfont, UK).

10 Altered (reduced immunogenicity) versions of the protein were constructed by site directed mutagenesis of the wild-type gene in pMEX8. Mutagenesis was conducted using short (18-mer) synthetic oligonucleotides obtained commercially (Genosys, Cambridge, UK) and the "quick-change" procedure and reagents from Stratagene (Cambridge, UK). Following site directed mutagenesis, DNA sequences of selected clones were confirmed as previously.

15 For expression of recombinant wild-type and recombinant variant INA2 proteins, pMEX8-INA2 expression plasmids were transformed into *E. coli* strain JA221 and cells grown and harvested using standard procedures (Sambrook J., Fritisch E.F. & Maniatis T. (1989) *ibid.*). Recombinant INA2 was prepared essentially as described previously (Grosfeld, H. *et al.*, in *Advances in Biotechnological Processes 4*, Mizrahi 20 A. & Van Wezel A. L. eds., pp59-78 Alan R. Liss Inc, New York (1985)) with minor modifications. Briefly, following high speed centrifugation, the supernatant was concentrated by 60% saturation of ammonium sulphate and then chromatographed on a 2.7 x 68cm Sephadex G-75 column equilibrated with PBS plus 0.5M NaCl. Fractions (8ml) were collected at a 1min/ml flow rate. Pooled fractions were further 25 purified using an immunoaffinity column as described previously (Grosfeld, H. *et al.*, (1985) *ibid.*). Purified proteins were assayed using SDS-PAGE analysis and functional activity (anti-viral activity) determined using biological assays as described previously (Shafferman, A. *et al.*, *J. Biol. Chem.* **262** 6227-6237 (1987)).

CLAIMS

1. A method of rendering a protein, or part of a protein, non-immunogenic, or less immunogenic, to a given species, the method comprising:

5

(a) determining at least part of the amino acid sequence of the protein;

10
10

(b) identifying in the amino acid sequence one or more potential epitopes for T cells ("T cell epitopes") which are found in an endogenous protein of the given species; and

(c) modifying the amino acid sequence to eliminate at least one of the T cell epitopes identified in step (b) thereby to reduce the immunogenicity of the protein or part thereof when exposed to the immune system of the given species.

15

2. A method as claimed in claim 1 wherein the given species is human.

3. A method according to claim 1 or 2, wherein the amino acid sequence is modified by modification of a peptide which binds to MHC class II molecules.

20

4. A method according to claim 1 or 2, wherein the amino acid sequence is modified by modification of a peptide which binds to MHC class I molecules.

25

5. A method as claimed in any one of claims 1 to 4, wherein the T cell epitopes are identified by computation.

6. A method as claimed in any one of claims 1 to 5, comprising additionally identifying and eliminating one or more potential T cell epitopes which are not found in an endogenous protein of the given species.

7. A method as claimed in any one of claims 1 to 6, wherein an epitope considered as not generally available to the immune system to gain tolerance is identified as a potential epitope for elimination.

5

8. A method as claimed in claim 7, wherein an epitope of an intracellular protein is identified as a potential epitope for elimination.

9. A method as claimed in any one of claims 1 to 8, wherein one or more B cell 10 epitopes is also identified as a potential epitope for elimination.

10. A method as claimed in any one of claims 1 to 9, wherein the protein is non-autologous.

15 11. A method as claimed in any one of claims 1 to 9, wherein the protein is autologous.

12. A method as claimed in any one of claims 1 to 11, wherein the protein is: a 20 protein with an enzymatic activity which has a beneficial therapeutic effect; a protein which is used to convert inactive drugs to active drugs within a living organism; a protein which is used to vaccinate whereby one or more immunogenic epitope is undesirable; a protein which performs as a carrier of other molecules within the living organism; or a protein which binds to other molecules within or introduced within the living organism in order to alter the biodistribution of the other molecules.

25 13. A method as claimed in any one of claims 1 to 12, wherein the protein is tested for desired activity.

14. A method as claimed in claim 1 comprising:

- I. Determining the amino acid sequence of the protein or a part thereof (if modification only of a part is required);
 - II. Identifying potential T cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of peptides to MHC molecules, determination of the binding of peptide:MHC complexes to the T cell receptors from the species to receive the therapeutic protein, testing of the protein or peptide parts thereof using transgenic animals with the MHC molecules of the species to receive the therapeutic protein, or testing with transgenic animals reconstituted with immune system cells from the species to receive the therapeutic protein;
 - III. By genetic engineering or other methods for producing modified proteins, altering the protein to remove one or more of the potential T cell epitopes and producing such an altered protein for testing;
 - IV. (optionally) Within step III., altering the protein to remove one or more of the potential B cell epitopes;
 - V. Testing altered proteins with one or more potential T cell epitopes (and optionally B cell epitopes) removed in order to identify a modified protein which has retained all or part of its desired activity but which has lost one or more T cell epitopes.
15. A method as claimed in any one of claims 1 to 14, wherein a T cell epitope is eliminated by alteration of one or more amino acids within the epitope itself.
20. A method as claimed in claim 15, wherein the alteration is amino acid substitution.
25. A method as claimed in claim 16, wherein the amino acid substitution is made

with reference to a homologous protein primary structure.

18. A method as claimed in claim 16, wherein the amino acid substitution is made on the basis of similar size and/or charge.

5

19. A method as claimed in claim 16, wherein the amino acid substitution is made with reference to *in silico* protein modelling techniques.

20. A method as claimed in claim 13, wherein a high-throughput method is used
10 for screening large numbers of modified proteins.

21. A molecule resulting from a method as claimed in any one of claims 1 to 20.

22. A molecule as claimed in claim 21 for use in medicine or diagnosis.

15

23. The use of a molecule as claimed in claim 21 in the manufacture of an therapeutic or diagnostic agent.

A**α-chain**

ALYTLITPAVLRTDTEEQILVEAHGDSTPKQLDI FVHDFPRKQKTLFQTRDMNPAGGMLVTP
TIEIPAKEVSTD SRQNQYVVVQVTGPQVRLEKVVLLSYQSSFLFI QTDKGIYTPGSPVLYR VF
SMDHNTSKMNKT VIVEFQTPEGILVSSNSVDLNFFWPYNLPDLVSLGTWRIVAKYEHS PENYT
AYFDV RKYVLP SFEVRL QPSEKFFYIDGNENFHV SITARYL IY GEEVEGVAFVLFGV KIDDAKK
SIPDSLTRIPII DGDGKATLK RD FRSRF PN LNE LVGHTLYASVTVM TESGSDMV VTEQSGIH
IVASPYQIHFTKTPK YFKPGMPYELTVYVTNPDGSPA AHVPV VSEAFHSMGTT LSDGTAKLIL
NIPLNAQSLP ITVRTN HGDLP RERQATKSMTAIAYQTQGGSGNYLHV AITSTEIKPGDNLPVN
FNVKG NANS LKQIKYFTYLILNKG KIFKVGRQPRRDGQNLVTMNLHITPD LI PSFRVAYYQV
GNNEI VADSVW DVKDT CMGTLVVKGDNL I QMPGAAMKIKLEGDP GARVGLVAVDKAVYVLND
KYKISQAKI WDTIEKSDFGCTAGSGQNNLGV FEDAGL ALT STN LNTK QRSA AKCPQ PAN

B**β-chain**

EIQMPTHKDLNLDITIELPDREVPIRYRINYENALLARTVETKLNQDITVTASGDGKATMTIL
TFYNAQLQEKA NCNKFH LNV SVE NIHLNAMGAKGALMLKICTRYLGEVDSTM II DISMLTG
FLPDAEDLTRL SKGVDRYI SRYEV DNNMAQKV AVIIYLNK VSHSEDECLHF KILKH FEVGFIQ
PGSVKVYSY NLDEK CTKFYHPD KGTG LLNK I CIGNVRCAGETCSSLNHQ ERI DVPLQIEKA
CETNVDYVYKTKL LRIE QDGNDI YVMDV LEVI KQGT DENPRAKTHQYI SQRKCQEA NLKV N
DDYLIWGSRS DLLPTK DKI SYI ITK NTWIERWP HEDECQEEFQKL CDDFAQFSY TLTE FGCP
T

C**γ-chain**

DDNEDGFIADSDII SRSDFPKSWLWLT KDLTEEPNSQGISSKTM SFYLRDSITTWWVLA VSFT
PTKGICVAEPYEIRVMKVFFIDLQMPYSVVKNEQVEIRAILHN YVN EDIYV RVELLYNPAFCS
ASTKGQRYRQQFPIK ALSSRAVPFVIVPLEQGLHDVEIKASVQEA LWS DGV RKKLV VPEGVQ
KSIVTIVKLD PRAKG VGGTQ LEVI KARKL DDR VPDT EITK II IQGDPVAQIIENSIDGSKLN
SIPD

FIGURE 1

Protein sequence of mature cobra venom factor

A = alpha chain

B = gamma chain

C = beta chain

ALYTLITPAVLRTDTEEQILVEAHGDSTPKQLDIFVHDFPRKQKTLFQTRVDMNPAGGMLVTP
TIEIPAKEVSTDQRQNQYVVVQVTGTQVRLEKVVLLSYQSSFLFIQTDKGIFTPGSPVLYRVF
SMDHNTSKMNKTIVEFQTPEGILVSSNSVDSLNFWPYNLPDLVSLGTWRIVAKYEHSPEINY
TAYFDVRKYVLPSEVIVEPTEKFYYIDGNENFHVSITARYLYGEEVEGVAFVLFGVKIDDALK
ISLPESLKRIPIIDGDGKATLSRDTFRSRFPNLNEVGKSLYVSATVITESGSDMVTEQSGI
HIVASPYQIHFTKTPKYFKPGMPYELTVFTNPDGSPAHHVPVVEAFHSMGTTLSDGTAKLI
LNIPLNAAQSLPITVVRTNHGDLPRERQATKSMTAIAYQTQGGSGNYLHVAITSTEIKPGDNLPV
NFNVKGNANSLAQIKYFTYLILNKGKIFKVGRCQPREPGQDLVVLNLHITPDLIPSFRLVAYYT
LIGASGNNEIVADSVWVDVKDSCVGSIVVKGDNLIQMPGAAMKIKLEGDPGARVGLVAVDKAV
FVLNDKYKISQAKIWDTVVEKADIGCTAGSGQNNLGVFEDAGLALTSTNLNTKQRSAAKCPQ
PAN

FIGURE 2

Protein sequence of an altered cobra venom factor α -chain.

DDNEDGFIADSDIIISRSDFPKSWLWLTSDLTEEPNSQGISSKTMFSYLKDSITTWEVLAVSFT
PTKGICVADPFEVTVMKVFFIDLQMPYSVVKNEQVEIRAILHNYVNEDLYVRVELLYNPAFC
ASTTGQRYRQQFPIKALSSRAVPPVIVPLEQGLHDVEVKAAYVHFISDGVRKKLVVPEGVQ
KSTVTIVKLDPRAKGVGQTQLEVIKARKLDDRVPDTEIETKIIIQGDPVAQIIENSIDGSKLN
SIPD

FIGURE 3

Protein sequence of an altered cobra venom factor γ -chain.

EIQMPTHKDLNLDITIELPDREVPIRYRINYENASLARTVETKLNQDFTVTASGDGKATMTIL
TFYNAQLQEAKANVCNKFDLNVSVENIHLNAMGAKNTMILKICTRYLGEVDSTMIIIDISMLTG
FLPDAEDLTRLSKGVDRYISRYEVDDNMAQKVAVIIFYLDKVSHSEDDCLHFKILKHFEVGFIQ
PGSVKVSYYNLDESCTRHYHPDKGTGLNKICIGNLCRCAGETCSSLNHQERVDVPLQIEKA
CETNVDYVYTKLLRIEEQDGNDYEYMDVLEVIKQGTDENQRAKTHQYISQRKCQEALNLKVN
DHYLIWGSRS DLLPTKDKISYIIGKDTWVEHWPEEDECQEEEFQKLCDDFAQFSYTLTEFGCP
T

FIGURE 4

Protein sequence of an altered cobra venom factor β -chain.

IAGPEWLLDRPSVNNSQLVSVAGTVGTQDISLKFFEIDLTSRPAHGGKTEQGLSPKS
KPFATDSGAMPHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFAD
KDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLK
DTKLLKTLAIGDTITSQELLAQAQSILNKTHPGTYIYERDSSIVTHDNDIFRTILPMQDE
FTYHVKNREQAYEINKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYV
DVNTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDD
TNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVSYLRYTGTPIPDNPNDK

FIGURE 5

Protein sequence of streptokinase from *Streptococcus equisimilis*

IAGPEWLLDRPSVNNSQLVSVAGTVGTQDISLKFFEIDLTSRPAHGGKTEQGLSPKS
KPFATDSGAMPHKLEKADLLKAKQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFAD
KDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLK
DTKLLKTLAIGDTITSQELLAQAQSILNKTHPGTYIYERDSSIVTHDNDIFRTILPMQDE
FTYHVKNREQAYEINKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKFV
DVNTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDD
TNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVSYLRYTGTPIPDNPNDK

FIGURE 6

Protein sequence of an altered streptokinase molecule.

SSSFDFKGKYKKGDDASYFEPTGPYLMVNVTGVDSKGNELLSPHAVEFPIKPGTTLTKEKIEYY
VEWALDATAYKEFRVVELDPSAKIEVTYYDKNKKKEETKSFPITEKGFVVVDLSEHIKNPGFN
LITKVVIEKK

FIGURE 7

Protein sequence of mature staphylokinase.

SSSFDFKGKYKEGDDASQFEPTGPYLMVNVTGVDSAGNALLSPHYVEFPIKPTTLTEERIKYYV
EWALDATAAAFAVVELDPSARVEVTYYDKNKKKEETKSFPITEKGFVVVDLSEHIKNPGFNL
FTKVVIEKK

FIGURE 8

Protein sequence of an altered staphylokinase molecule.

DVSFRLSGATTSYGVFIKNLREALPYERKVYNIPLLRSSISGSGRYTLLHILTNYADETISVA
DVDTNVYIMGYLAGDVSYFFNEASATEAAKFVFKDAKKVTLPPSGNYERLQTAAGKIRENIP
LGLPALDSAITTLYYTASSAASALLVLIQSTAESARYKFIEQQIGKRVDKTFLPSLATISLE
NNWSALSKQIQIASTNNGQFESPVVLIDGNNQRVSITNASARVVTNSNIALLNRRNNIAAIGED
ISMTLIGFEHGLYGI

FIGURE 9

Protein sequence of wild-type bryodin 1.

DVSFSMSGATTSYGVFKNLREALPFERKVYNIPLLRSSISGSGRYTLLHILTNYADETISVA
DVDTNVYIMGYLAGDVSYFFNEASATEAAKFVFKDAKKVTLPPSGNYERLQTAAGKIRENIP
LGLPALDSAITTLYYTASSAASALLVLIQSTAESARFKFIEQQIGKRVDKTFLPSLATISLE
NNWSALSKQIQIASTNNGQFESPVVLVDGNNQSVSITNASARVVTNSNVALLNRNNIAAVGED
ISMTLIGFEHGLYGI

FIGURE 10

Protein sequence of an altered bryodin 1 molecule.

CDLPQTHSLGSRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQI
FNLFSTKDSSAAWDETLLDKFYTELYQQLNDEACVIQGVGVTEPLMKEDSILAVRKYFQRI
TLYLKEKKYSPCAEVVRAEIMRSFSLSTNLQESLRSK

FIGURE 11

Protein sequence of mature human interferon alpha 2

CDLPQTHSLGSRTTMLLAQMRKISLFYCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQI
FLLFSTKDSSAAWDETLLDKFYTELYQQLNDEACVIQGVGVTEPLMKEDSILAVRKYFQRI
TLYLKEKKYSPCAEVVRAEIMRSFSLSTNLQESLRSK

FIGURE 12

Protein sequence of an altered human interferon alpha 2 molecule

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/435, 14/315, 16/46, G01N 33/563	A3	(11) International Publication Number: WO 00/34317 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/GB99/04119		(74) Agents: SHEARD, Andrew, Gregory et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).
(22) International Filing Date: 8 December 1999 (08.12.99)		
(30) Priority Data: 9826925.1 8 December 1998 (08.12.98) GB 9902139.6 2 February 1999 (02.02.99) GB		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (<i>for all designated States except US</i>): BIOVATION LIMITED [GB/GB]; Investment House, 6 Union Row, Aberdeen AB10 1DQ (GB).		
(72) Inventors; and		
(75) Inventors/Applicants (<i>for US only</i>): CARR, Francis, Joseph [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). ADAIR, Fiona, Suzanne [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). HAMILTON, Anita, Anne [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB). CARTER, Graham [GB/GB]; Biovation Limited, Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU (GB).		
		(Published <i>With international search report.</i>)
		(88) Date of publication of the international search report: 17 August 2000 (17.08.00)

(54) Title: METHOD FOR REDUCING IMMUNOGENICITY OF PROTEINS

(57) Abstract

It is known that proteins, or parts of them, may be rendered non- or less immunogenic to humans or other species by identifying one or more potential T cell epitopes and eliminating them by amino acid modification. Conventionally, certain epitopes may be retained in a protein sequence if the peptides constituting such epitopes are present in endogenous human protein, since they would be recognised as "self". However, it has now been found that even self epitopes may give rise to immune reactions. The invention provides for their elimination, for example by recombinant DNA technology, to render them more useful for administration to humans, for example for therapeutic or diagnostic purposes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

In. National Application No PCT/GB 99/04119
--

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/435 C07K14/315 C07K16/46 G01N33/563

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 52976 A (BIOVATION LTD ;CARR FRANCIS J (GB)) 26 November 1998 (1998-11-26) cited in the application abstract; claims; example 7	1-23
X	WO 92 10755 A (NOVONORDISK AS) 25 June 1992 (1992-06-25) claims	1-23
X	EP 0 721 982 A (LEUVEN RES & DEV VZW ;COLLEN DESIRE JOSE (BE)) 17 July 1996 (1996-07-17) abstract	1-23
X	EP 0 699 755 A (CENTRO IMMUNOLOGIA MOLECULAR) 6 March 1996 (1996-03-06) abstract	1-23

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
---	--

30 May 2000

06/06/2000

Name and mailing address of the ISA	Authorized officer
-------------------------------------	--------------------

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Cervigni, S

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/04119

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9852976	A 26-11-1998	AU 7539398 A			11-12-1998
		EP 0983303 A			08-03-2000
		GB 2339430 A			26-01-2000
WO 9210755	A 25-06-1992	AT 170630 T			15-09-1998
		AU 9052891 A			08-07-1992
		BR 9107206 A			03-11-1993
		CA 2095852 A			06-06-1992
		DE 69130113 D			08-10-1998
		DE 69130113 T			12-05-1999
		EP 0561907 A			29-09-1993
		FI 932561 A			04-06-1993
		JP 6502994 T			07-04-1994
		US 5766898 A			16-06-1998
EP 0721982	A 17-07-1996	AU 705119 B			13-05-1999
		AU 4437796 A			24-07-1996
		BG 101556 A			27-02-1998
		BR 9606724 A			13-01-1998
		CA 2206479 A			11-07-1996
		CN 1168156 A			17-12-1997
		CZ 9702104 A			12-11-1997
		EA 121 B			27-08-1998
		WO 9621016 A			11-07-1996
		EP 0721013 A			10-07-1996
		EP 0793723 A			10-09-1997
		FI 972862 A			03-09-1997
		HU 9802915 A			29-03-1999
		JP 8289790 A			05-11-1996
		NO 973083 A			04-08-1997
		PL 321181 A			24-11-1997
		SK 89297 A			06-05-1998
		US 5695754 A			09-12-1997
		US 5951980 A			14-09-1999
EP 0699755	A 06-03-1996	CA 2153135 A			31-12-1995
		CN 1133886 A			23-10-1996
		JP 8280387 A			29-10-1996
		US 5712120 A			27-01-1998